Background: An important feature of the InPen™ Smart Insulin Pen (SIP) is its ability to track active insulin, enabling opportunities to safely calculate correction doses any time after a bolus. This study investigated the frequency of users delivering correction doses and its impact on glycemia when delivered within 3 hours of a previous dose in both adult and pediatric InPen users with T1D or T2D.

Methods: A retrospective cohort analysis was performed using deidentified sensor glucose (SG) data from N=857 individuals with sufficient SG data (at least 70% of SG data each day), ≥3 boluses per day, and ≥1 correction dose per day on average in the 60-to-90th day period after starting InPen-use Jan 2022-Dec 2022. Each user's proportion of corrections delivered within 3 hours of a previous dose (notated PC3) was calculated, and users were split into two groups based on the median of PC3. Glycemic outcomes including percentage TIR, 70-180 mg/dL), TBR, <70 mg/dL and TAR, >180 mg/dL and average SG were determined from the latest 14 days of device use. Comparisons between groups were conducted using t-tests (Mann Whitney U test when data were non-normal) at ≤0.05. Duration of insulin action (DIA) distributions were also described.

Results: The median PC3 of the overall group was 32.5% (range 0-100%). The upper half of the group (≥32.5%) showed significantly higher TIR (57.8% vs 50.5%, p<0.0001), lower TAR (40.2% vs 47.8%, p<0.0001), and lower SG (175.7 mg/dL vs 190.8 mg/dL, p<0.0001), compared with the lower half (<32.5%). There was no significant change in TBR (1.9% vs 1.8%, p=0.77). Of the 857 users, 55.2% had DIA >3 hours (3.6±0.84; range 2-8). The average DIA of the upper half and the lower half were 3.4±0.8 hours and 3.8±0.8 hours, respectively (NS).

Conclusion: InPen™ SIP users who delivered at least 1 correction dose a day within 3 hours of a previous dose achieved overall higher TIR without an increase in TBR, when compared to those who administered correction insulin >3 hours after their previous dose.

Disclosure

G. Im: Employee; Medtronic. M. Smith: Employee; Medtronic. J. Macleod: Employee; Medtronic. R. A. Vigersky: Employee; Medtronic.

© 2023 by the American Diabetes Association
2023
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.